ZA200107318B - Controlled-releae compositions of betahistine. - Google Patents
Controlled-releae compositions of betahistine. Download PDFInfo
- Publication number
- ZA200107318B ZA200107318B ZA200107318A ZA200107318A ZA200107318B ZA 200107318 B ZA200107318 B ZA 200107318B ZA 200107318 A ZA200107318 A ZA 200107318A ZA 200107318 A ZA200107318 A ZA 200107318A ZA 200107318 B ZA200107318 B ZA 200107318B
- Authority
- ZA
- South Africa
- Prior art keywords
- controlled
- release tablet
- betahistine
- granulation
- fatty compound
- Prior art date
Links
- 229960004536 betahistine Drugs 0.000 title claims description 33
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical group CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 title claims description 22
- 239000000203 mixture Substances 0.000 title claims description 12
- 238000013270 controlled release Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 10
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 8
- 238000007909 melt granulation Methods 0.000 claims description 8
- 238000007906 compression Methods 0.000 claims description 6
- 230000006835 compression Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000007908 dry granulation Methods 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 3
- 229920002126 Acrylic acid copolymer Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 150000002334 glycols Chemical class 0.000 claims description 2
- 150000002433 hydrophilic molecules Chemical class 0.000 claims description 2
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 238000000338 in vitro Methods 0.000 description 14
- 239000000454 talc Substances 0.000 description 14
- 229910052623 talc Inorganic materials 0.000 description 14
- 229940049654 glyceryl behenate Drugs 0.000 description 13
- 239000008119 colloidal silica Substances 0.000 description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 9
- 229960000541 cetyl alcohol Drugs 0.000 description 7
- 235000021355 Stearic acid Nutrition 0.000 description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
- 239000008117 stearic acid Substances 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920003112 high viscosity grade hydroxypropyl cellulose Polymers 0.000 description 2
- 229920003113 low viscosity grade hydroxypropyl cellulose Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940031954 dibutyl sebacate Drugs 0.000 description 1
- -1 dihydrochloride Chemical compound 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1999MI000454A IT1309591B1 (it) | 1999-03-05 | 1999-03-05 | Composizioni a rilascio controllato di betaistina. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200107318B true ZA200107318B (en) | 2002-09-04 |
Family
ID=11382165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200107318A ZA200107318B (en) | 1999-03-05 | 2001-09-04 | Controlled-releae compositions of betahistine. |
Country Status (37)
| Country | Link |
|---|---|
| EP (1) | EP1158963B1 (it) |
| JP (1) | JP2002538197A (it) |
| KR (1) | KR20010102498A (it) |
| CN (1) | CN1165295C (it) |
| AR (1) | AR029154A1 (it) |
| AT (1) | ATE231392T1 (it) |
| AU (1) | AU762532B2 (it) |
| BG (1) | BG105807A (it) |
| BR (1) | BR0008739A (it) |
| CA (1) | CA2364226A1 (it) |
| CO (1) | CO5170438A1 (it) |
| CZ (1) | CZ299510B6 (it) |
| DE (1) | DE60001266T2 (it) |
| DK (1) | DK1158963T3 (it) |
| EE (1) | EE200100453A (it) |
| ES (1) | ES2189739T3 (it) |
| GE (1) | GEP20033078B (it) |
| HK (1) | HK1042246B (it) |
| HR (1) | HRP20010650A2 (it) |
| HU (1) | HUP0200243A2 (it) |
| ID (1) | ID30127A (it) |
| IL (1) | IL145263A0 (it) |
| IT (1) | IT1309591B1 (it) |
| MX (1) | MXPA01008893A (it) |
| NO (1) | NO319135B1 (it) |
| NZ (1) | NZ513949A (it) |
| PE (1) | PE20001547A1 (it) |
| PL (1) | PL196290B1 (it) |
| PT (1) | PT1158963E (it) |
| RU (1) | RU2248791C2 (it) |
| SI (1) | SI1158963T1 (it) |
| SK (1) | SK284584B6 (it) |
| TR (1) | TR200102566T2 (it) |
| UA (1) | UA65652C2 (it) |
| WO (1) | WO2000053162A1 (it) |
| YU (1) | YU64001A (it) |
| ZA (1) | ZA200107318B (it) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060153915A1 (en) * | 2003-01-23 | 2006-07-13 | Amorepacific Corporation | Sustained-release preparations and method for producing the same |
| SI1493435T1 (sl) | 2003-07-04 | 2008-10-31 | Formenti Farmaceutici Spa | Betahistinski sestavki s kontroliranim sproĺ äśanjem |
| JP2007533733A (ja) | 2004-04-22 | 2007-11-22 | モル リサーチ アプリケーションズ リミテッド | 食物摂取管理の方法 |
| US7728015B2 (en) | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
| EP1771159A4 (en) * | 2004-07-22 | 2009-04-29 | Amorepacific Corp | SLOW RELEASE PREPARATIONS CONTAINING TOPIRAMATE AND PROCESS FOR PRODUCING THE SAME |
| JP2006176461A (ja) * | 2004-12-24 | 2006-07-06 | Dai Ichi Seiyaku Co Ltd | 粒状物 |
| EP2293794B1 (en) | 2008-05-27 | 2013-05-22 | The University of Melbourne | Methods of treating mammals with eustachian tube dysfunctions |
| EP2314296A1 (en) * | 2009-10-22 | 2011-04-27 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Orally Disintegrating Tablets of Betahistine |
| EP2491930A1 (en) * | 2011-02-25 | 2012-08-29 | Deva Holding Anonim Sirketi | Pharmaceutical combination of betahistine and trimetazidine |
| DE102012105528A1 (de) | 2012-06-25 | 2014-01-02 | Hennig Arzneimittel Gmbh & Co. Kg | Arzneiform zur Freisetzung von Wirkstoffen |
| WO2015053620A1 (en) * | 2013-10-07 | 2015-04-16 | Disphar International B.V. | Betahistine composition |
| EP3431078B1 (en) * | 2017-07-20 | 2021-01-20 | Intas Pharmaceuticals Limited | Non-pulsatile prolonged-release betahistine oral solid compositions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2432313A1 (fr) * | 1978-08-01 | 1980-02-29 | Foulhoux Pierre | Nouvelle forme galenique de la betahistine et son procede d'obtention |
| GB2280604B (en) * | 1993-07-02 | 1997-04-30 | Resource Medical Limited | Processing of active agents |
| PL191399B1 (pl) * | 1996-10-28 | 2006-05-31 | Gen Mills Inc | Sposób kapsułkowania lub osadzania składnika w osnowie w procesie ciągłym, sposób kapsułkowania i/lub osadzania składników w osnowie opartej na węglowodanach, sposób kapsułkowania i/lub osadzania składników w osnowie oraz kapsułka |
-
1999
- 1999-03-05 IT IT1999MI000454A patent/IT1309591B1/it active
-
2000
- 2000-02-28 DE DE60001266T patent/DE60001266T2/de not_active Expired - Fee Related
- 2000-02-28 SK SK1249-2001A patent/SK284584B6/sk unknown
- 2000-02-28 HU HU0200243A patent/HUP0200243A2/hu unknown
- 2000-02-28 KR KR1020017011271A patent/KR20010102498A/ko not_active Application Discontinuation
- 2000-02-28 GE GEAP20006082A patent/GEP20033078B/en unknown
- 2000-02-28 TR TR2001/02566T patent/TR200102566T2/xx unknown
- 2000-02-28 CZ CZ20013186A patent/CZ299510B6/cs not_active IP Right Cessation
- 2000-02-28 CN CNB008046190A patent/CN1165295C/zh not_active Expired - Fee Related
- 2000-02-28 ID IDW00200101790A patent/ID30127A/id unknown
- 2000-02-28 YU YU64001A patent/YU64001A/sh unknown
- 2000-02-28 IL IL14526300A patent/IL145263A0/xx unknown
- 2000-02-28 EE EEP200100453A patent/EE200100453A/xx unknown
- 2000-02-28 PT PT00910723T patent/PT1158963E/pt unknown
- 2000-02-28 AU AU32831/00A patent/AU762532B2/en not_active Ceased
- 2000-02-28 CA CA002364226A patent/CA2364226A1/en not_active Abandoned
- 2000-02-28 DK DK00910723T patent/DK1158963T3/da active
- 2000-02-28 UA UA2001085807A patent/UA65652C2/uk unknown
- 2000-02-28 MX MXPA01008893A patent/MXPA01008893A/es unknown
- 2000-02-28 AT AT00910723T patent/ATE231392T1/de not_active IP Right Cessation
- 2000-02-28 BR BR0008739-4A patent/BR0008739A/pt not_active Application Discontinuation
- 2000-02-28 PL PL350232A patent/PL196290B1/pl unknown
- 2000-02-28 SI SI200030050T patent/SI1158963T1/xx unknown
- 2000-02-28 RU RU2001124607/15A patent/RU2248791C2/ru not_active IP Right Cessation
- 2000-02-28 JP JP2000603651A patent/JP2002538197A/ja active Pending
- 2000-02-28 EP EP00910723A patent/EP1158963B1/en not_active Expired - Lifetime
- 2000-02-28 WO PCT/EP2000/001642 patent/WO2000053162A1/en active IP Right Grant
- 2000-02-28 NZ NZ513949A patent/NZ513949A/en unknown
- 2000-02-28 ES ES00910723T patent/ES2189739T3/es not_active Expired - Lifetime
- 2000-03-02 CO CO00015153A patent/CO5170438A1/es not_active Application Discontinuation
- 2000-03-03 PE PE2000000181A patent/PE20001547A1/es not_active Application Discontinuation
- 2000-03-03 AR ARP000100974A patent/AR029154A1/es active IP Right Grant
-
2001
- 2001-08-09 BG BG105807A patent/BG105807A/bg unknown
- 2001-09-04 ZA ZA200107318A patent/ZA200107318B/en unknown
- 2001-09-04 HR HR20010650A patent/HRP20010650A2/hr not_active Application Discontinuation
- 2001-09-04 NO NO20014301A patent/NO319135B1/no unknown
-
2002
- 2002-05-31 HK HK02104045.5A patent/HK1042246B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1083885B1 (en) | Delavirdine tablet formulation | |
| ES2465478T3 (es) | Composiciones farmacéuticas que comprenden brivaracetam | |
| JPH11505542A (ja) | 毎日一回投与するための、非晶質活性成分の一定のかつ制御された放出を行う三相型医薬製剤 | |
| US9642808B2 (en) | Extended release compositions comprising mycophenolate sodium and processes thereof | |
| AU2017220971A1 (en) | Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof | |
| JP2009500317A (ja) | 放出特性改良医薬組成物およびその製造方法 | |
| ZA200107318B (en) | Controlled-releae compositions of betahistine. | |
| EP2394644B1 (en) | Trimetazidine Formulation With Different Release Profiles | |
| EP3569225A1 (en) | Solid dispersion containing ritonavir | |
| US11878078B2 (en) | Instant release pharmaceutical preparation of anticoagulant and preparation method therefor | |
| WO2011000518A1 (en) | Pharmaceutical composition comprising desloratadine | |
| EP2594260A1 (en) | Solid preparations comprising sirolimus with desired bioavailability and method for its preparation | |
| WO2001008665A1 (en) | Paracetamol controlled-release compositions | |
| EP2846778B1 (en) | Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate | |
| AU2013201986A1 (en) | Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients | |
| PL176474B1 (pl) | Preparat farmaceutyczny o kontrolowanym uwalnianiu i sposoby wytwarzania preparatu farmaceutycznego o kontrolowanym uwalnianiu |